Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Alimentary Pharmacology & Therapeutics · 2026-10-08
DOI: 10.1111/apt.71020 ↗At a glance
Leserbrief in Alimentary Pharmacology & Therapeutics, published online on 2026-10-08. Written by Anastasios Koulaouzidis and 1 co-authors. Institution: Department of Clinical Research, University of Southern Denmark (SDU), Odense, Denmark. Cited 1 times so far (Crossref); 4 references.
Abstract (original language)
Abstract non disponibile.
Subjects
Author keywords
Authors and institutions
- Department of Clinical Research, University of Southern Denmark (SDU), Odense, Denmark.
- Department of Gastroenterology, Pomeranian Medical University in Szczecin (PUM), Szczecin, Poland.
- Endoklinika, the Center for Digestive Diseases, Szczecin, Poland.
ORCID profiles: Anastasios Koulaouzidis, Wojciech Marlicz
Cite
APA
Koulaouzidis, A., & Marlicz, W. (2026). Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71020
Vancouver
Koulaouzidis A, Marlicz W. Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71020
BibTeX
@article{Koulaouzidis2026,
author = {Koulaouzidis, Anastasios and Marlicz, Wojciech},
title = {Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71020}
}
EUVIMED